TELA Bio Unveils Groundbreaking OviTex PRS: Revolutionizing Plastic and Reconstructive Surgery


MALVERN, PATELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company, recenlty announced the launch of their OviTex PRS Long-Term Resorbable product. OviTex PRS Long-Term Resorbable is intended for implantation to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcement in plastic and reconstructive surgery. The device is supplied sterile and is intended for one time use.

OviTex PRS Long-Term Resorbable supplements the Company’s existing OviTex PRS portfolio, which includes OviTex PRS Permanent and OviTex PRS Short-Term Resorbable configurations. The OviTex PRS portfolio is designed to improve outcomes by facilitating functional tissue remodeling while controlling the degree and direction of stretch. OviTex PRS Long-Term Resorbable enhances the OviTex PRS portfolio with specific design features, including bi-directional stretch and a fully resorbable, long-term polymer for reinforcement.

“We are excited to offer expanded clinical utility of the OviTex PRS portfolio to surgeons and patients in plastic and reconstructive surgery,” said Antony Koblish, President and CEO of TELA Bio. “OviTex PRS Long-Term Resorbable is an important addition to the portfolio as it will allow surgeons to address clinical indications that require longer term reinforcement while avoiding the use of permanent materials.”

With 6,800+ implantations at over 400 healthcare facilities, OviTex PRS is the only biologic reinforced with interwoven polymer sutures designed specifically for plastic and reconstructive surgery. This next-generation reinforced biologic is purposefully designed for consistency in stretch, permeability, and handling while facilitating functional remodeling. The OviTex PRS portfolio provides multiple resorption, stretch, and shape offerings to meet the unique needs of each patient.

READ:  HSN Launches Livestream Video Shopping Experience on Sling Freestream

“The OviTex PRS portfolio provides surgeons with an innovative and effective platform for soft-tissue reconstruction,” said Dr. Howard Langstein, MD, Professor of Plastic Surgery University of Rochester Medical Center. “My experience with OviTex PRS has been very positive and the addition of a long-term resorbable reinforcement option further expands the treatment options for my patients.”

To learn more, visit

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.